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Background/aim: We aimed to investigate the factors affecting the mortality of patients aged 65 years or older who were hospitalized
with the diagnosis of new coronavirus pneumonia (COVID-19).
Materials and methods: This is a retrospective study of patients 65 years old or older with COVID-19 who were hospitalized in İstanbul
University-Cerrahpaşa, Cerrahpaşa Medical Faculty Hospital, between March 11 and May 28, 2020. Demographic, clinical, treatment,
and laboratory data were extracted from electronic medical records. We used univariate and multivariate logistic regression methods to
explore the risk factors for in-hospital death.
Results: A total of 218 patients (112 men, 106 women) were included, of whom 166 were discharged and 52 died in hospital. With
univariate analysis, various clinical features and laboratory variables were found to be significantly different (i.e. P < 0.05). In multivariate
logistic regression analysis the following were independently associated with mortality: present malignancy [odds ratio (OR) = 4.817,
95% confidence interval (CI) = 1.107–20.958, P: 0.036]; dyspnea (OR = 4.652, 95% CI = 1.473–14.688, P: 0.009); neutrophil/lymphocyte
ratio (NLR; OR = 1.097, 95% CI = 1.012–1.188, P: 0.025); the highest values of C-reactive protein (CRP; OR = 1.006, 95% CI =
1.000–1.012, P: 0.049), lactate dehydrogenase (LDH; OR = 1.002, 95% CI = 1.001–1.004, P: 0.003), and creatinine levels (OR = 1.497,
95% CI = 1.126–1.990, P: 0.006); oxygen saturation (SpO2) values on admission (OR = 0.897, 95% CI = 0.811–0.993, P: 0.036); and
azithromycin use (OR = 0.239, 95% CI = 0.065–0.874, P: 0.031).
Conclusion: The presence of malignancy; symptoms of dyspnea; high NLR; highest CRP, LDH, and creatinine levels; and low SpO2 on
admission predicted mortality. On the other hand, azithromycin use was found to be protective against mortality. Knowing the causes
predicting mortality will be important to treat future cases more successfully.
Key words: COVID-19, geriatrics, hospitalized patients, mortality, risk factors

1. Introduction
In December 2019, the pneumonia epidemic that was
centered in the city of Wuhan, China, was defined as
coronavirus disease 2019 (COVID-19) due to the newly
defined severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) agent. This virus is thought to have been
transmitted from a zoonotic infection, such as SARS-CoV
or Middle East respiratory syndrome coronavirus (MERSCoV) that is, transmitted from animals to humans.
Coronaviruses are single chain, positive polarity, enveloped
RNA viruses. Because of their positive polarity, they do not
contain the RNA-dependent RNA polymerase enzyme;

however, they encode this enzyme in their genome.
They have rod-like extensions on their surfaces [1]. The
disease spectrum caused by a coronavirus in humans
can range from simple colds to severe acute respiratory
syndrome. It may cause clinical presentations in humans
and animals with various degrees of respiratory, enteric,
hepatic, nephrotic, and neurological involvements [2]. The
World Health Organization (WHO) accepted COVID19 as a global pandemic and declared an emergency on
March 11, 2020.1 That same day, the first case was reported

WHO (2021). WHO Timeline – COVID-19 [online]. Website
https://www.who.int/news-room/detail/08-04-2020-who-timeline---covid-19 [accessed 11 March 2020].
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by Republic of Turkey Ministry of Health.2 Although
several predictions have been made about the end of the
pandemic’s progression and the occurrence of the second
wave, much remains uncertain [3].
As is known, patients 65 years of age or over can be
very frail due to their comorbidities and age-related
physiological changes [4]. As a matter of fact, the data
obtained from scientific studies have revealed that older
adults are among the groups most at risk for the disease
[5]. It causes higher mortality rates, especially in older
people with other health problems, such as cardiovascular
disease, chronic respiratory system disease, diabetes, or
cancer [6]. Compared to people in a younger age group,
the symptoms and course of the disease in older adults
may also differ. Imperial College London’s COVID- 19
Response Team reports that those who show symptoms
in their 70s are more than 20 times more likely to be
hospitalized than those in their 20s [7]. In this study, we
aimed to investigate the factors affecting the mortality
and survival of older patients hospitalized with the
diagnosis of COVID-19 in COVID inpatient clinics or the
intensive care unit. Furthermore, we aimed to ensure early
precautions will be taken in a second wave.
2. Methods
2.1. Participants
The participants were identified from inpatients of the
İstanbul University-Cerrahpaşa, Cerrahpaşa Medical
Faculty Hospital, by searching the hospital’s electronic
medical records between March 11 and May 28, 2020.
Beginning March 11, the facility was changed to a
pandemic hospital. Patients aged 65 years or older who
were diagnosed with COVID- 19 and discharged or died in
hospital by May 28, 2020, were enrolled in this study. The
diagnoses of all included patients were confirmed using
the Diagnosis and Treatment Guideline for COVID-19
published by Republic of Turkey Ministry of Health.2
2.2. Data collection
Demographic data, application complaints, comorbidity,
medication use, and smoking history were extracted from
electronic medical records and retrospectively reviewed
and analyzed. CURB-65 scores were calculated on
admission. The abbreviation stands for the following, with
one point assigned for a “yes”: confusion, Urea > 41 mg/dL,
respiratory rate > 30 breaths/min, blood pressure < 90/60
mm/Hg, and age ≥ 65. Complete blood count, neutrophil/
lymphocyte ratio (NLR), C-reactive protein (CRP),
procalcitonin, ferritin, lactate dehydrogenase (LDH), urea,
creatinine, liver function tests, albumin, international

normalized ratio (INR), fibrinogen, and D-dimer levels were
recorded on admission, as were the highest values of CRP,
creatinine, D-dimer, LDH, and ferritin levels. The number
of hospitalized days at intensive care units and inpatient
clinics, number of days intubated, electrocardiogram
(ECG) changes, presence of delirium, presence of pressure
ulcers during hospitalization, oxygen treatment types,
and oxygen saturation (SpO2) values on admission were
noted from the clinical course of the patient files. Also
recorded were COVID-19 polymerase chain reaction
(PCR) test results, thorax computed tomography (CT)
findings, used medicine for the treatment of COVID-19,
and adverse effects and complications. Thorax CT findings
were staged by a radiology specialist in accordance with
the reporting recommendations of the Radiological
Society of North America Expert Consensus. According
to the findings in the images, they were classified as
typical, indeterminate, atypical, or negative in appearance
[8]. Patients with a typical, indeterminate, or atypical
appearance were accepted as thorax CT positive and
received COVID treatment. The mortality and discharge
rates were examined. Patients who had no fever for the last
three days, whose clinical findings and laboratory values
decreased, and who had been hospitalized for at least
seven days were discharged.
2.3. Statistical analysis
Data were expressed as medians (interquartile range) for
continuous variables and counts and frequencies [number
(percentage)] for categorical variables. A comparison
of categorical variables between the discharged and
deceased groups was performed using Pearson’s χ2 test
with continuity correction or Fisher’s exact test, where
appropriate. The Mann–Whitney U test was used to
compare differences in continuous variables between the
two groups because they were all nonnormally distributed.
Multivariable logistic regression modeling was used to
explore independent risk factors for death. Regression
analysis was performed for parameters associated with
mortality within their own groups (comorbidities,
symptoms, etc.). Multivariate regression analysis was also
performed for the parameters that were significant in these
analyses. Although some parameters, which were not
associated with mortality in our study, related to mortality
in the literature (age, hypertension) were also included in
the multivariate regression analysis. Continuous variables
were treated as continuous measures in the model.
Statistical analyses were performed using SPSS version
21.0 (IBM Corporation, Armonk, NY, USA). Differences
were considered to be statistically significant when twosided P values were less than 0.05.

2
Republic of Turkey Ministry of Health (2021). COVID-19
Information Page [online]. Website https://covid19bilgi.saglik.
gov.tr/depo/rehberler/COVID-19_Rehberi.pdf [accessed 11
March 2020].

3. Results
The first cases in Turkey were reported on March 11. By
May 28, the total number of cases had reached 160,979,
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and the total number of deaths reported was 4461.3
Between the same dates, 1808 cases and 86 deaths related
to COVID-19 were reported at İstanbul UniversityCerrahpaşa, Cerrahpaşa Medical Faculty Hospital, a
pandemic hospital. Of the patients, 908 were hospitalized
in the COVID inpatient clinics or intensive care unit, and
251 of the inpatients were over 65 years of age. Thirty-three
of these 251 geriatric patients were excluded from the
study because COVID PCR or thorax CT tests could not
confirm the diagnoses despite clinical findings. The other
218 patients (112 men, 106 women) were included. Sixtyeight of the patients were hospitalized in the intensive
care unit and 150 in the inpatient clinics. Among them,
52 died (34 men, 18 women) specifically, 70.5% (n: 48) of
the patients who were hospitalized in the intensive care
unit and 2.6% (n: 4) in the inpatient clinics. Mortality
was 9.5% among all COVID-19 patients (n: 86) in the
inpatient clinics or intensive care unit, regardless of age,
while in the geriatric group, this rate increased to 23.9%.
The patients were divided into three age groups ranging
from 65–74 (n: 107), 75–84 (n: 86), and 85 or more (n: 25)
years. Furthermore, this study investigated sex differences
by placing participants into two groups: female and male.
However, no significant difference was found between the
sex and age groups in terms of mortality.
As shown in Table 1, the most common comorbidities
were hypertension (66.0%), type 2 diabetes mellitus
(31.7%), coronary artery disease (CAD; 31.2%), chronic
obstructive pulmonary disease (COPD; 19.3%), congestive
heart failure (CHF; 17.0%), and malignancy (14.7%). Of
the patients, 18.8% were using an angiotensin-converting
enzyme inhibitor (ACEI), and 25.7% were using an
angiotensin receptor blocker (ARB). Polypharmacy
was present in 49.5% of the patients, and no significant
difference was found between age or sex groups. Also,
24.0% of patients had a fever, 39.0% had a cough, and
41.0% had shortness of breath. Other symptoms were less
common (Table 1).
The patients’ laboratory values on admission and the
highest values are shown in Table 2. The COVID PCR tests
were positive in 46.7% of the patients, and COVID findings
were positive in thorax CTs in 91.3% of the patients. For 83
patients (38.0%), both their COVID PCR and thorax CT
tests were positive. In 19 patients (8.7%), COVID PCR was
positive while thorax CT was negative, and in 116 patients
(53.2%), COVID PCR was negative while thorax CT was
positive. The blood pressure of 5.0% of the patients was
greater than 90/60 mmHg on admission.
The oxygen treatment types applied to patients
during hospitalization are shown in Table 3. During
3
Republic of Turkey Ministry of Health (2021). COVID-19
Information Page [online]. Website https://covid19bilgi.saglik.
gov.tr/depo/rehberler/COVID-19_Rehberi.pdf [accessed 28
March 2020].
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hospitalization, ECG changes were observed in 18.3%,
delirium in 12.4%, and pressure ulcers in 3.2% of the
patients. For COVID-19 treatment, 100% of patients
used hydroxychloroquine, 78.0% azithromycin, 70.6%
oseltamivir, 58.3% favipiravir, 7.3% lopinavir/ritonavir,
12.4% tocilizumab, 7.8% corticosteroid, and 78.4%
anticoagulants. Adverse drug reactions occurred in 8.7%
of the patients, and the majority of these adverse effects
were prolonged QT on ECG (6.9%).
Thus far, this results section has profiled this study’s 218
geriatric patients. Now, the focus shifts to the relationships
between mortality and the patients’ characteristics. The
mortality rate of men was higher than that of women
(P: 0.021). However, no significant relationship was found
between age groups and death. In terms of comorbidities,
although our study found no such relationship, some
epidemiological studies have shown that hypertension
is associated with increased mortality and morbidity in
COVID-19 patients. On the other hand, our study did
find CHF, malignancy, and dementia to be more common
in patients who died (respectively, P: 0.035, < 0.001, and
0.03). Polypharmacy was found in 49.5% of the patients
and was significantly higher in the patients who died
(P: 0.021).
There was no relationship between the excess number
of symptoms and death. When the symptoms were
evaluated one by one, a significant relationship was found
between cough and death and between dyspnea and death
(respectively, P: 0.001 and < 0.001).
This study also investigated possible relationships
between mortality and laboratory values. If the patient’s
levels of lymphocytes were lower and the white blood
cell count and NLR were higher on admission, these
changes in values were significantly related to mortality
(respectively, P: 0.001, 0.002, and < 0.001). CRP, ferritin,
and LDH on admission were all associated with mortality
(respectively, P: < 0.001, 0.001, and < 0.001), as were their
highest values (respectively, P: < 0.001, 0.001, and < 0.001).
The highest value of D-dimer was also associated with
mortality (P: < 0.001). In patients who died, INR, aspartate
aminotransferase (AST), and alanine aminotransferase
(ALT) values on admission were significantly higher, and
albumin values were lower. Urea and creatinine levels on
admission and the highest creatinine values were higher in
the patients who died (respectively, P: < 0.001, 0.04, and
< 0.001).
CURB-65 is a severity score containing five variables
used to determine the severity of community-acquired
pneumonia [9]. In this study, mortality was significantly
higher in patients with a CURB-65 score of four to five
than in other groups (P: < 0.001). It was observed that
patients with lower baseline SpO2 values (P: < 0.001)
and whose CURB-65 scores were four to five died more
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Table 1. Demographics and clinical presentation in patients with COVID-19 pneumonia.
Characteristics

All patients

Recovery and discharge Death

n

218

166 (76.1 %)

52 (23.9 %)

Age, Mean (25–75)
Age, groups, n (%)
65–74
75–84
≥85
Sex
Male n (%)
Female n (%)
Comorbidity n (%)

75.3 (70–81)

75 (69–81)

74.5 (70–80)

107 (49.1 %)
86 (39.4 %)
25 (11.5 %)

81 (48.8 %)
69 (41.6 %)
16 (9.6 %)

26 (50 %)
17 (32.7 %)
9 (17.3 %)

112 (51.4 %)
106 (48.6 %)

78 (47 %)
88 (53 %)

34 (65.4 %)
18 (34.6 %)

P value
0.421

0.243
0.021

Hypertension

145 (66.5 %)

113 (68.1 %)

32 (61.5 %)

0.403

Diabetes

69 (31.7 %)

57 (34.3 %)

12 (23.1 %)

0.128

CAD

68 (31.2 %)

49 (29.5 %)

19 (36.5 %)

0.340

CHF

37 (17 %)

23 (13.9 %)

14 (26.9 %)

0.035

Malignancy

32 (14.7 %)

14 (8.4 %)

18 (34.6 %)

<0.001

COPD

42 (19.3 %)

28 (16.9 %)

14 (26.9 %)

0.109

Chronic renal disease

28 (12.8 %)

19 (11.4 %)

9 (17.3 %)

0.270

Dementia

24 (11 %)

14 (8.4 %)

10 (19.2 %)

0.03

Cerebrovascular disease

19 (8.7 %)

13 (7.8 %)

6 (11.5 %)

0.406

Polypharmacy

108 (49.5 %)

75 (45.2 %)

33 (63.5 %)

0.021

ACEI n (%)

41 (18.8 %)

29 (17.5 %)

12 (23.1 %)

0.367

ARB n (%)

56 (25.7 %)

48 (28.9 %)

8 (15.4 %)

0.051

Smoking

44 (20.2 %)

30 (18.1 %)

14 (26.9 %)

0.165

Presence of symptoms, n (%)

207 (95 %)

156 (94 %)

51 (98.1 %)

0.238

Fever

53 (24.3 %)

41 (24.7 %)

12 (23.1 %)

0.812

Cough

85 (39 %)

75 (45.2 %)

10 (19.2 %)

0.001

Dsypnea

90 (41.3 %)

55 (33.1 %)

35 (67.3 %)

<0.001

Fatigue

28 (12.8 %)

23 (13.9 %)

5 (9.6 %)

0.425

Known contact history

17 (7.8 %)

15 (9 %)

2 (3.8 %)

0.373

Nausea/vomiting

10 (4.6 %)

8 (4.8 %)

2 (3.8 %)

0.770

Loss of consciousness

10 (4.6 %)

6 (3.6 %)

4 (7.7 %)

0.255

Sore throat

9 (4.1 %)

9 (5.4 %)

0

0.119

Myalgia

8 (3.7 %)

8 (4.8 %)

0

0.107

Diarrhea

6 (2.8 %)

4 (2.4 %)

2 (3.8 %)

0.581

Chills

6 (2.8 %)

5 (3 %)

1 (1.9 %)

0.675

Headache

1 (0.5 %)

1 (0.6 %)

0

0.575

CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; ACEI, angiotensin
converting enzyme inhibitor; ARB, angiotensin receptor blocker.

(P < 0.001). COVID PCR and thorax CT positivity were
not associated with mortality.
As predicted, it was found that patients died more if
they had a high number of days of hospitalization and

intubation in the intensive care unit and used noninvasive
and invasive mechanical ventilators. However, no
relationship was found between the total number of
hospitalization days and mortality. The use of a mask with
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Table 2. Laboratory findings in patients with COVID-19 pneumonia.
Laboratory results, mean (25–75) All patients

Recovery and discharge

Death

P value

Hemoglobin, g/dL

11.9 (10.6–13.1)

12.2 (10.6–13.3)

11.3 (10.3–12.2)

0.073

WBC, 10^3/μL

7.45 (5.3–10.7)

6.9 (5–8.8)

10.5 (7.4–13.5)

0.001

Platelets, 10^3/μL

211000 (160550–263550) 217000 (160900–263100) 196800 (148725–277500) 0.191

Lymphocyte, 10^3/μL

1.2 (0.8–1.7)

1.3 (0.9–1.9)

0.9 (0.5–1.3)

0.002

NLR, 10^3/μL

4.15 (2.27–8.78)

3.3 (1.8–5.2)

10.7 (5–18.2)

<0.001

Ferritin, ng/mL

279.9 (102–685.7)

231 (91.7–582)

532 (282–1459)

0.001

Highest ferritin, ng/mL
D-dimer, mg/L

516.6 (189.6–1264)

354.3 (165.8–822.5)

1543 (690–2000)

0.001

1.45 (0.69–3.8)

1.17 (0.5–3.05)

3.4 (1.3–7.8)

0.052

Highest D-dimer, mg/L

3.97 (1.48–12.07)

2.69 (1.14–7.21)

11.9 (6.4–34.3)

<0.001

Procalcitonin, ng/mL

0.13 (0.06–0.43)

0.09 (0.04–0.26)

0.55 (0.23–1.76)

0.260

LDH, IU/L

279.5 (210–405)

249 (201–352)

419 (293–638)

<0.001

Highest LDH, IU/L

432 (304–697.7)

405 (269.7–559.2)

726 (488–1185)

<0.001

CRP, mg/L

53 (21.7–120)

36 (147–947)

132 (53–177)

<0.001

Highest CRP, mg/L

120.1 (42.7–231.9)

82.14 (33.01–162.6)

260 (210–325)

<0.001

INR

1.1 (1.03–1.2)

1.1 (1.01–1.2)

1.2 (1.1–1.4)

0.013

Urea, mg/L

90 (86–94)

9 (7–14.2)

12 (5.2–18)

<0.001

Creatinin, mg/L

1.02 (0.8–1.4)

1 (0.78–1.26)

1.24 (0.8–1.97)

0.04

Highest creatinin, mg/L

1.33 (0.95–2.02)

1.19 (0.91–1.61)

1.24 (0.8–1.97)

<0.001

AST, IU/L

29.5 (19–45)

25.8 (18–38)

45 (30–57)

0.004

ALT, IU/L

17 (12–32)

16 (12–28)

23 (12.5–56.5)

0.038

Fibrinogen, mg/dL

456 (357–573)

451 (346–557)

499 (395–582)

0.088

Albumin, gr/dL

3.64 (3.2–4)

3.75 (3.3–4.05)

3.18 (2.84–3.79)

<0.001

WBC, white blood cell; NLR, neutrophil/lymphocyte ratio; LDH, lactate dehydrogenase; CRP, C-reactive protein; INR, international
normalized ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

a reservoir was associated with mortality (P: < 0.001).
It was found that patients who used azithromycin,
one of the drugs used for COVID- 19 treatment, died less
(P: 0.009). In contrast, the use of favipiravir was found to
be higher in the patients who died (P: < 0.001).
In multivariate logistic regression analysis to detect
the factors predicting mortality among older patients with
COVID-19, malignancy; dyspnea; NLR; the highest values
of CRP, creatinine, and LDH; azithromycin use; and SpO2
values on admission were independently associated with
mortality (Table 4).
4. Discussion
This study investigated factors affecting mortality in
hospitalized older adult patients with COVID-19. Many
studies have shown that mortality increases with increasing
age [10]. In a study with 72,314 cases, the overall mortality
rate was 2.3%, but it was 8% in patients 70–79 years old
and 14.5% in patients ≥ 80 years old [11]. In another
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analysis by the Korean Centers for Disease Control and
Prevention, the overall case fatality rate (CFR) in 11,344
patients with confirmed cases on May 28, 2020, was 2.4%;
however, it was much higher in older adults (10.9% in
patients 70–79 years and 26.6% in patients ≥ 80 years).4 In
a report published by the Italian Institute of Higher Health,
the total CFR on March 26, 2020, was four times higher
than in Korea or China (9.2%); however, the increase in
mortality with age was similar to that in Korea and China.
CFR was less than 1% in the 50–69 age group, 16.9% in the
70–79 age group, and 24.4% in the 80 and older age group.5
In our study, no significant difference was found between
mortality and age groups. This may be due to the fact that
the number of patients in the 85 years and older age group
is lower than the other groups. Also, another reason may
be that comorbidities are independent of age.
The COVID-19 mortality rate was higher in male
patients than female patients in this study (P: 0021). This
finding contradicts another study concerning geriatric
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Table 3. Clinical findings and treatment modalities in patients with COVID-19 pneumonia.
Clinical findings and treatment modalities
Hospitalized days numbers in intensive care
unit
Intubated days numbers

All patients

Recovery and
discharge

Death

P value

10.09 (4–14)

8 (3.25–11.7)

10 (4–16.75)

<0.001

9.05 (2.75–13.25)

5.5 (1.75–8)

8.5 (3–14)

<0.001

Total hospitalized days numbers

10 (7–15.25)

9 (7–14.25)

12 (5.25–18)

0.326

SpO2 % on admission
Blood pressure on admission, n (%)
≤ 90/60
<90/60
CURB65, n (%)
1–2
3
4–5
COVID PCR positive, n (%)

94 (89–97)

95 (91–97)

88 (77–94)

<0.001

14 (6.4 %)
204 (93.6)

11 (6.6 %)
155 (93.4 %)

3 (5.7 %)
49 (94.3 %)

0.493

156 (71.6%)
41 (18.8 %)
21 (9.6 %)
102 (46.7 %)

135 (81.3 %)
25 (15.1 %)
6 (3.6 %)
75 (45 %)

21 (40.4 %)
16 (30.8 %)
15 (28.8 %)
27 (51.9 %)

<0.001

199 (91.3 %)

151 (91 %)

48 (92.3 %)

0.06

19 (8.7 %)
24 (11 %)
40 (18.3 %)
135 (61.9 %)

15 (9 %)
14 (8.4 %)
30 (18.1 %)
107 (64.5 %)

4 (7.6 %)
10 (19.2 %)
10 (19.2 %)
28 (53.8 %)

Thorax CT positive, n (%)
Thorax CT Classification, n (%)
0 (negative)
1 (atypical)
2 (indeterminate)
3 (typical)
Oxygen treatment, n (%)

0.561

0.094

Nasal

126 (57.8 %)

98 (59 %)

28 (46.2 %)

0.508

Mask with a reservoir

26 (11.9 %)

7 (4.2 %)

19 (36.5 %)

<0.001

High Flow

15 (6.9 %)

9 (5.4 %)

6 (11.5 %)

0.204

NIMV

24 (11 %)

8 (4.8 %)

16 (30.8 %)

<0.001

IMV

57 (26.1 %)

10 (6 %)

47 (90.4 %9

<0.001

Delirium

27 (12.4 %)

19 (11.5 %)

8 (15.7 %)

0.431

Pressure ulcer

7 (3.2 %)

5 (3 %)

2 (3.8 %)

0.766

ECG change

40 (18.3 %)

28 (16.9 %)

12 (23.1 %)

0.313

Hydroxychloroquine

215 (98.6 %)

166 (100 %)

52 (100 %)

0.425

Azithromycin

170 (78%)

136 (82.4 %)

34 (65.4 %)

0.009

Oseltamivir

154 (70.6 %)

117 (71.3 %)

37 (71.2 %)

0.979

Favipiravir

127 (58.3 %)

80 (48.5 %)

47 (90.4 %)

<0.001

Lopinavir/ritonavir

16 (7.3 %)

13 (7.8 %)

3 (5.8 %)

0.619

Tocilizumab

27 (12.4 %)

22 (13.3 %)

5 (9.6 %)

0.479

Anticoagulants

171 (78.4 %)

132 (79.5 %)

39 (75 %)

0.635

Corticosteroids

17 (7.8 %)

10 (6 %)

7 (13.5 %)

0.081

COVID treatment, n (%)

SpO2, oxygen saturation; COVID PCR, new coronavirus pneumonia polymerase chain reaction; CT, computerized tomography; NIMV,
noninvasive mechanical ventilation; IMV, invasive mechanical ventilation; ECG, electrocardiography.

patients and the factors affecting mortality, which found
no significant relationship between sex and death [12].
Furthermore, our study’s multivariate regression analysis
did not point to sex as a factor that predicts mortality.

However, in a large-scale study involving 1663 patients,
mortality was higher in men than in women, as in our
study [13]. In addition, previous studies have reported
that men are more affected by SARS and MERS infections.
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Table 4. Logistic regression analysis of COVID-19 mortality risk factors.
Univariate analysis

Multivariate analyses

Variable

OR (95% CI)

P value

OR (95% CI)

P value

Age, year

1.018 (0.976–1.062)

0.410

0.991 (0.913–1.075)

0.819

Sex

0.469 (0.246–0.897)

0.022

0.614 (0.186–2.022)

0.423

Hypertension

0.750 (0.393–1.433)

0.384

0.317 (0.79–1.274)

0.106

Malignancy

5.748(2.605–12.681)

<0.001

4.817(1.107–20.958)

0.036

Dementia

2.585 (1.072–6.235)

0.035

3.252(0.673–15.711)

0.142

Dsypnea

4.155 (2.140–8.067)

<0.001

4.652(1.473–14.688)

0.009

Polypharmacy

2.107 (1.109–4.004)

0.023

1.741 (0.475–6.384)

0.403

NLR, 10^3/μL

1.192 (1.122–1.267)

<0.001

1.097 (1.012–1.188)

0.025

Highest D-dimer, mg/L

1.049 (1.026–1.072)

<0.001

1.001 (0.961–1.042)

0.968

Highest CRP, mg/L

1.014 (1.01–1.018)

<0.001

1.006 (1.000–1.012)

0.049

Highest LDH, IU/L

1.003 (1.002–1.005)

<0.001

1.002 (1.001–1.004)

0.003

Highest creatinin, mg/L

1.627 (1.283–2.063)

<0.001

1.497 (1.126–1.990)

0.006

SpO2 % on admission

0.850 (0.799–0.903)

<0.001

0.897 (0.811–0.993)

0.036

Azithromycin

0.403 (0.200–0.809)

0.011

0.239 (0.065–0.874)

0.031

One of the reasons for this situation may be that women
have different immune responses due to sex or pay more
attention to leading a healthy life. Another reason may be
that malignancy was detected more frequently in males
in our patient group (P: 0.033), and malignancy was
associated with mortality.
Among the comorbidities, malignancy was significantly
associated with mortality (OR = 4.817, 95% CI = 1.107–
20.958, P: 0.036), which was consistent with other studies’
findings. A study comparing COVID-19 patients with
and without cancer history found that malignancy was
an independent risk factor for mortality, similar to our
study [14]. This result may be due to the different immune
and inflammatory responses of patients with a history of
cancer.
The angiotensin-converting enzyme 2 (ACE2) has
been shown to be a coreceptor for viral entry of SARSCoV-2, suggesting that it has a role in the pathogenesis of
COVID-19 [15]. Therefore, ACEI and ARB use are thought
to increase COVID-19 mortality and morbidity. However,
some studies have shown that ACEIs prescribed at the clinic
do not inhibit ACE2, which acts as a carboxypeptidase
[16]. Similarly, in our study, no relationship was found
between ACEI and ARB use and mortality.
In a study comparing patients infected with
COVID-19 with and without dementia, dementia was
significantly associated with mortality [17]. Although
regression analysis did not predict mortality in our study,
it was observed that dementia was significantly higher in
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patients who died. Since it is difficult to identify symptoms
of atypical COVID- 19 in dementia patients, the interval
between the onset of symptoms and hospital admission
may have been prolonged, which may have adversely
affected the prognosis.
There is no clear consensus for polypharmacy, and
there are different definitions. Some of these definitions
are the use of two or more drugs within 240 days, using
four or more drugs, or using five or more drugs [18]. Since
the use of five or more drugs is a more accepted definition,
we defined polypharmacy as the use of five or more
drugs in our study. There is no research in the literature
investigating the effect of polypharmacy on COVID-19
prognosis. In our study, while polypharmacy was found
to be significantly high in patients who died, it was not
one of the parameters predicting mortality in multivariate
regression analysis.
Symptoms were present in 95.0% of the patients,
but there was no relationship between the presence of
symptoms and mortality. Since almost all the patients
had symptoms, we can say that there was no significant
relationship between mortality and whether there were
symptoms. Although fever is the most common symptom
in the general population (98.0%) [19], the most common
symptom in our study was dyspnea (41.0%). Due to
decreased immune system response in older adults,
fever response to infections is also generally reduced. In
our study, 24.0% of patients had a fever, which is a much
lower percentage than the overall COVID-19 patients.
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Among the symptoms, a significant relationship was only
found between dyspnea and mortality (OR = 4.652, 95%
CI = 1.473–14.688, P: 0.009). Dyspnea in those who died
was twice as frequent as in those who were discharged. This
result may indicate that a COVID-19 patient presenting
with dyspnea will have a worse course of infection than
another patient without dyspnea.
There are studies in the literature about the laboratory
predictors of death from COVID- 19. In our study’s
multivariate regression analysis, it was determined
that NLR and the highest values of CRP, creatinine,
LDH levels may predict mortality. NLR is a marker of
systemic inflammation predicting prognosis in various
pathological conditions [20]. Recently, in communityacquired pneumonia, NLR has been found to have more
prognostic power than known infection markers, such
as CRP, white blood cell count, and neutrophil count
[21]. There are also studies showing that the lymphocyte
count affects the prognosis of COVID-19 disease [22].
Research has reported that severe COVID-19 cases had a
higher neutrophil count and lower lymphocyte count than
nonsevere patients, so NLR tends to be higher in patients
with severe infection [23]. In addition to these studies, our
study found NLR to be one of the predictors of mortality
in COVID-19 patients (OR = 1.097, 95% CI = 1.012–
1.188, P: 0.025). NLR may be a parameter that can be easily
used to predict mortality since it can be calculated with
a simple hemogram test. Some studies have reported that
an elevated CRP is related to COVID-19 mortality [24].
In this study, the highest CRP values were associated with
mortality (OR = 1.006, 95% CI = 1.000–1.012, P: 0.049).
A cytokine storm occurs during virus invasion and can
interact with excessive neutrophil infiltration, leading to
the formation of harmful inflammatory processes. The
immune system is suppressed, and the T lymphocyte
response decreases. As a result, accompanying bacterial
infections occur. These conditions may be the reason why
elevated CRP and NLR predict mortality.
Similar to some studies, in this study, the relationship
between high D-dimer values and mortality was
determined [25]. Research has shown that the risk of both
arterial and venous thromboembolism increases, especially
in patients with a severe course of COVID-19 [26]. This
may be the reason why a high D-dimer level is found to
be associated with mortality. In response, anticoagulants
have been included in the COVID-19 treatment protocols.
Higher LDH values are not surprising in COVID-19
patients who died (OR = 1.002, 95% CI = 1.001–1.004,
P: 0.003). There is reliable evidence that increased LDH
values reflect the degree of pulmonary damage in patients
with acute respiratory distress syndrome. Also, these
data have been reported with SARS [27]. It was reported
that multiorgan failure may be seen in severe COVID-19

cases [28]. The fact that the highest creatinine values in
our study were associated with mortality may actually be
a result of serious disease (OR = 1.497, 95% CI = 1.126–
1.990, P: 0.006).
It is already known that hypoxemia is a sign of poor
prognosis in pulmonary diseases, and the indicators for
hypoxemia are used to evaluate the severity of COVID-19
[19]. Therefore, it is not surprising that the lower SpO2
values on admission predicted mortality in our study
(OR = 0.897, 95% CI = 0.811–0.993, P: 0.036). A mask
with a reservoir is used in inpatient clinics to stave off
transferring to intensive care unit those patients who
worsen in the service follow-up and whose SpO2 with
nasal oxygen does not increase. In our study, there was
a higher mortality rate in patients using a mask with
reservoir (P: < 0.001). It may result from delaying the
patient’s timely arrival in intensive care, or from using
the mask on patients whose clinic situations have already
deteriorated.
In a study comparing patients who did not use
any medication to patients who used azithromycin,
hydroxychloroquine, or both azithromycin and
hydroxychloroquine, using azithromycin alone or in
combination with hydroxychloroquine did not affect
mortality [29]. Another study found that mortality
increased in those using only hydroxychloroquine
compared to those using hydroxychloroquine and
azithromycin [30]. Similarly, in our study, patients who
used azithromycin died less, and azithromycin use had a
protective effect on mortality in the multivariate logistic
regression analysis (OR = 0.239, 95% CI = 0.065–0.874,
P: 0.031). Azithromycin is effective against Zika and Ebola
viruses in vitro [31,32]. It prevents serious respiratory
infections when administered to patients with viral
infections. It can be protective against mortality for
both this reason and because it can prevent bacterial
superinfections. Favipiravir use was found to be higher
in patients who died (P: < 0.001). This may be due to the
fact that favipiravir has been given to patients whose SpO2
and clinical situation have deteriorated despite the classic
triple treatment (hydroxychloroquine, azithromycin, and
oseltamivir).
In this study, in which the factors affecting mortality
in geriatric patients with COVID-19 were investigated,
appropriate and contributing data were obtained from
the literature. The limitations of our study were that the
number of patients in the three age groups was dissimilar,
and information about the time between a patient’s onset
of complaints and admission to the hospital was not
available in the files. Our study needs to be supported
by prospective studies, which will be done by evaluating
frailty, an essential parameter in geriatric patients.
In conclusion, the COVID-19 outbreak has been
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declared a global pandemic. The future course of
COVID-19, when the first wave will end, and whether
there will be a second wave are all important questions.
The answers are not yet known. However, it is a known
fact that COVID-19 is more serious and fatal in the older
adults. Therefore, knowing the causes predicting mortality
is important so that health care providers and others can
be more conscious of them in future cases. Older patients
with COVID-19 should be monitored more carefully, and
more care should be taken in factors affecting mortality
reported in our study and other studies in the literature.
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